ERCP in babies: Low risk of post-ERCP pancreatitis - results from a multicentre survey.


Journal

United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807

Informations de publication

Date de publication:
02 2020
Historique:
entrez: 28 3 2020
pubmed: 28 3 2020
medline: 22 6 2021
Statut: ppublish

Résumé

Endoscopic retrograde cholangiopancreatography (ERCP) is rarely performed in newborns, and the risk of post-ERCP pancreatitis (PEP) has not been defined in this age group. We therefore performed a European multicentre analysis of PEP rates and risk factors in children aged ≤1 year. Based on a sample size estimation, 135 consecutive ERCPs in 126 children aged ≤1 year were evaluated from five European centres, and the first ERCP per child analysed. All ERCPs and clinical reports were reviewed manually for PEP and associated risk factors. All ERCPs were performed by endoscopists with high ERCP expertise. No PEP was observed (0/126, 0.0%, CI 0-2.9%) despite the formal presence of multiple risk factors and despite lack of PEP prophylaxis (except one patient having received a pancreatic duct stent). The PEP rate was significantly lower than the PEP rate expected in adults with similar risk factors. ERCP in children aged ≤1 year is safe in terms of PEP. The PEP risk is significantly lower in children aged ≤1 year than in adults, therefore no PEP prophylaxis seems to be needed in young children. Risk factors from adults may not apply to children under 1 year. Reluctance to perform diagnostic ERCP in suspected biliary anomalies should not be based on presumed PEP risk.

Sections du résumé

BACKGROUND AND AIMS
Endoscopic retrograde cholangiopancreatography (ERCP) is rarely performed in newborns, and the risk of post-ERCP pancreatitis (PEP) has not been defined in this age group. We therefore performed a European multicentre analysis of PEP rates and risk factors in children aged ≤1 year.
PATIENTS AND METHODS
Based on a sample size estimation, 135 consecutive ERCPs in 126 children aged ≤1 year were evaluated from five European centres, and the first ERCP per child analysed. All ERCPs and clinical reports were reviewed manually for PEP and associated risk factors. All ERCPs were performed by endoscopists with high ERCP expertise.
RESULTS
No PEP was observed (0/126, 0.0%, CI 0-2.9%) despite the formal presence of multiple risk factors and despite lack of PEP prophylaxis (except one patient having received a pancreatic duct stent). The PEP rate was significantly lower than the PEP rate expected in adults with similar risk factors.
CONCLUSIONS
ERCP in children aged ≤1 year is safe in terms of PEP. The PEP risk is significantly lower in children aged ≤1 year than in adults, therefore no PEP prophylaxis seems to be needed in young children. Risk factors from adults may not apply to children under 1 year. Reluctance to perform diagnostic ERCP in suspected biliary anomalies should not be based on presumed PEP risk.

Identifiants

pubmed: 32213056
doi: 10.1177/2050640619874187
pmc: PMC7006005
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-80

Références

Gut. 2013 Jan;62(1):102-11
pubmed: 23100216
Gastrointest Endosc. 2015;81(6):1408-16
pubmed: 25686874
United European Gastroenterol J. 2017 Nov;5(7):1024-1029
pubmed: 29163969
Endoscopy. 2017 Jan;49(1):83-91
pubmed: 27617420
Endoscopy. 2010 Feb;42(2):121-6
pubmed: 20140829
Endoscopy. 2014 Sep;46(9):799-815
pubmed: 25148137
J Pediatr Gastroenterol Nutr. 2012 Aug;55(2):142-5
pubmed: 22790901
J Hepatol. 2009 Dec;51(6):1055-60
pubmed: 19726099

Auteurs

Martin Goetz (M)

Innere Medizin I, Universitätsklinikum Tübingen, Tübingen, Germany.
Medizinische Klinik IV, Kliniken Böblingen, Böblingen, Germany.

Philipp Andersen (P)

Innere Medizin I, Universitätsklinikum Tübingen, Tübingen, Germany.

Jacques Bergman (J)

Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands.

Nicola Frei (N)

Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands.

Arthur Schmidt (A)

Department of Medicine II, Faculty of Medicine, University of Freiburg; Medical Centre, Freiburg, Germany.

Georg Kähler (G)

Central Interdisciplinary Endoscopy, Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.

Peter Martus (P)

Institut für Klinische Epidemiologie und Angewandte Biometrie (IKEaB), Universität Tübingen, Tübingen, Germany.

Alexander Dechêne (A)

Klinik für Innere Medizin 6, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany.
Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH